JPWO2020041607A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020041607A5
JPWO2020041607A5 JP2021509764A JP2021509764A JPWO2020041607A5 JP WO2020041607 A5 JPWO2020041607 A5 JP WO2020041607A5 JP 2021509764 A JP2021509764 A JP 2021509764A JP 2021509764 A JP2021509764 A JP 2021509764A JP WO2020041607 A5 JPWO2020041607 A5 JP WO2020041607A5
Authority
JP
Japan
Prior art keywords
formulation
hmga2
patient
tgfβ
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534195A5 (https=
JP2021534195A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047734 external-priority patent/WO2020041607A1/en
Publication of JP2021534195A publication Critical patent/JP2021534195A/ja
Publication of JPWO2020041607A5 publication Critical patent/JPWO2020041607A5/ja
Publication of JP2021534195A5 publication Critical patent/JP2021534195A5/ja
Pending legal-status Critical Current

Links

JP2021509764A 2018-08-22 2019-08-22 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置 Pending JP2021534195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721249P 2018-08-22 2018-08-22
US62/721,249 2018-08-22
PCT/US2019/047734 WO2020041607A1 (en) 2018-08-22 2019-08-22 Treatment of triple negative breast cancer with targeted tgf-b inhibition

Publications (3)

Publication Number Publication Date
JP2021534195A JP2021534195A (ja) 2021-12-09
JPWO2020041607A5 true JPWO2020041607A5 (https=) 2022-08-29
JP2021534195A5 JP2021534195A5 (https=) 2022-08-29

Family

ID=69591342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509764A Pending JP2021534195A (ja) 2018-08-22 2019-08-22 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置

Country Status (12)

Country Link
US (1) US20210196822A1 (https=)
EP (1) EP3840776A4 (https=)
JP (1) JP2021534195A (https=)
KR (1) KR20210046716A (https=)
CN (1) CN113271962A (https=)
AU (1) AU2019325593A1 (https=)
BR (1) BR112021003093A2 (https=)
CA (1) CA3110276A1 (https=)
IL (1) IL280958A (https=)
MX (1) MX2021002006A (https=)
SG (1) SG11202101663WA (https=)
WO (1) WO2020041607A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230365653A1 (en) * 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof
CN121319180A (zh) * 2020-07-28 2026-01-13 乐普生物科技股份有限公司 靶向PD-L1和TGF-β的双功能分子
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
KR20230020041A (ko) 2021-08-02 2023-02-10 숙명여자대학교산학협력단 miR-181a 억제제 및 커큐민을 유효성분으로 포함하는 삼중음성유방암 치료용 조성물
TW202330626A (zh) * 2021-09-30 2023-08-01 大陸商貝達藥業股份有限公司 雙特異性抗體及其應用
CN115671314A (zh) * 2022-11-16 2023-02-03 中南大学 一种抗血管生成靶向黑磷纳米片的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG166768A1 (en) * 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
WO2014205184A2 (en) * 2013-06-19 2014-12-24 University Of Miami Classification system, methods and kit for classifying. predicting and treating breast cancer
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
WO2016145294A1 (en) * 2015-03-12 2016-09-15 The University Of Chicago Methods for determining prognosis for breast cancer patients
CA3001903A1 (en) * 2015-10-13 2017-04-20 The Scripps Research Institute Therapeutic targeting of casein kinase 1.delta. in breast cancer

Similar Documents

Publication Publication Date Title
JP2021534195A5 (https=)
Wagner et al. PPARs and angiogenesis—implications in pathology
JP7597384B2 (ja) 膀胱癌の治療方法
CN110168077B (zh) 用于治疗下肢外周动脉疾病的细胞悬液
KR20000070572A (ko) 혈관형성 유도용 아데노바이러스 벡터의 다중 부위 운반
CN107266551B (zh) 一种mg53突变体及其制备方法和应用
JPH09500652A (ja) 固形腫瘍悪性疾患治療用の細胞ワクチンおよび使用法
KR20200010609A (ko) 종양성 질병들에 대한 치료
Nayeri et al. Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
KR20080007642A (ko) 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
JPWO2020041607A5 (https=)
JP2021523096A5 (https=)
EP1320384A1 (en) The synergetic effects of hgf and antibacterial treatment
Dave et al. Ultrasound-guided intracardiac injection of human mesenchymal stem cells to increase homing to the intestine for use in murine models of experimental inflammatory bowel diseases
CA3243885A1 (en) COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR CANCER TREATMENT
Tufoni et al. Prolonged albumin administration in patients with decompensated cirrhosis: The amount makes the difference
RU2021107205A (ru) ЛЕЧЕНИЕ ТРОЙНОГО НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ ПУТЕМ НАПРАВЛЕННОГО ИНГИБИРОВАНИЯ TGF-β
CN117100742B (zh) Rhodiolin在制备治疗人甲状腺乳头状癌药物中的应用
CN114081945A (zh) 一种治疗肿瘤疾病的联合用药组合物及应用
JPWO2019222252A5 (https=)
TWI882612B (zh) 藥物組合及其應用
US20040086492A1 (en) Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt
Li et al. Pseudoaneurysm of the abdominal aorta due to brucella infection: Next-generation sequencing diagnosis and endovascular treatment
Öberg Neuroendocrine gastroenteropancreatic tumours: current views on diagnosis and treatment